Book a Meeting

Discovery of Antibody and Peptide Targeting Schistosoma

With the years of experience in anti-parasite biomolecular discovery, Creative Biolabs is confident in offering the best services for the discovery of antibody and peptide targeting Schistosoma. Our well-established Anti-Parasite Biomolecular Discovery provides the most comprehensive tools such as display technologies, antigen-specific B lymphocytes cytometry and hybridoma, and serves as one-stop solution for the generation of antibody and peptide targeting parasite.

Schistosomiasis is caused by infection with human helminth parasites of the genus Schistosoma and is one of the 17 neglected tropical diseases identified by WHO. The disease affects over 200 million people in more than 70 developing tropical countries and 750 million people are at risk of infection. Although the disease can be effectively treated with the drug of choice Praziquantel (PZQ), reinfection occurs rapidly after mass drug administration (MDA). Currently, an effective vaccine used singly or in combination with therapy is the optimal approach against Schistosoma.

Schistosoma-specific Targets for Antibody/Peptide Discovery

  • Cathepsin D aspartic protease (CatD)
  • The major digestive enzyme of Smansoni is a cathepsin D aspartic protease (CatD). In S. mansoni and S. japonicum, CatD plays an integral role in the initiation of the digestion cascade within the gastrodermis of the flukes. In a mouse model of schistosomiasis, vaccination with recombinant forms of S. japonicum CatD can significant reduce the total number of worm in vivo and relieving infection.

    Molecular model of Sm-CatD. Fig.1 Molecular model of Sm-CatD (Dougall et al. 2014).

  • Circulating cathodic antigen (CCA)
  • Circulating cathodic antigen (CCA) is a genus-specific glycoconjugate associated with the gut of the worm. It is regurgitated from worms into the circulatory system and levels of CCA are related to the presence and intensity of schistosome infection. CCA crude antigen, recombinant CCA and CCA peptide can be used for detection antibodies production, establishing the diagnosis method for S. mansoni.

  • Thioredoxin glutathione reductase (TGR)
  • TGR in plathelminthes such as S. mansoni and S. japonicum has been revealed to play a critical role in thiol-disulfide redox homeostasis. It is reported that TGR is essential for S. japonicum survival and regarded as a potential target for development of novel drugs against S. japonicum. A study has identified an anti-S. japonicum peptide, JIPDys1 (aa, WPHNWWPHFKVK), by screening a phage display peptide library using S. japonicum TGR as a target.

The dimer structure model of S. japonicum TGR Fig.2 The dimer structure model of S. japonicum TGR (Song et al. 2018).

Discovery of Antibody and Peptide Targeting Schistosoma

Creative Biolabs is a well-recognized leader in the field of discovery of antibody and peptide targeting parasite. Based on our innovative platform, we can provide the best anti-parasite monoclonal antibodies in a short period of time with exceptionally high specificity and affinity. Furthermore, we also provide a comprehensive list of premade peptide libraries which help to discover anti-parasite peptides. Please contact us for more information and a detailed quote.

References

  1. Dougall, A.M.; et al. Lipid core peptide targeting the cathepsin D hemoglobinase of Schistosoma mansoni as a component of a schistosomiasis vaccine. Hum Vaccin Immunother. 2014, 10(2):399-409.
  2. Song, L.J.; et al. Identification of peptide antagonists to thioredoxin glutathione reductase of Schistosoma japonicum. BioMed Research International. 2018, 2018(2):1-8.
For Research Use Only. We do not provide direct services or products for patients.
Related Services:
Online Inquiry
For Research Use Only. We do not provide direct services or products for patients.

Contact Us
Contact Us
  • (USA)
    (UK)
    (Germany)
  • Global Locations